120 related articles for article (PubMed ID: 37551741)
1. The design, synthesis, biological evaluation, and molecular docking of new 5-aminosalicylamide-4-thiazolinone hybrids as anticancer agents.
Othman SA; Abou-Ghadir OF; Ramadan WS; Mostafa YA; El-Awady R; Abdu-Allah HHM
Arch Pharm (Weinheim); 2023 Oct; 356(10):e2300315. PubMed ID: 37551741
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, photophysical properties, anticancer evaluation, and molecular docking studies of new pyrimidine linked 4-arylidene-thiazolidin-4-ones as potent anticancer agents.
Jame R
Luminescence; 2024 Jan; 39(1):e4672. PubMed ID: 38286597
[TBL] [Abstract][Full Text] [Related]
4. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
5. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
Kassab AE; Hassan RA
Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
[TBL] [Abstract][Full Text] [Related]
6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
7. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
9. New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies.
Abd El-Wahab HAA; Mansour HS; Ali AM; El-Awady R; Aboul-Fadl T
Bioorg Chem; 2022 Mar; 120():105622. PubMed ID: 35091290
[TBL] [Abstract][Full Text] [Related]
10. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors.
Sayed MTM; Halim PA; El-Ansary AK; Hassan RA
Drug Dev Res; 2023 Sep; 84(6):1299-1319. PubMed ID: 37357422
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
13. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition.
Amin MM; Abuo-Rahma GEA; Shaykoon MSA; Marzouk AA; Abourehab MAS; Saraya RE; Badr M; Sayed AM; Beshr EAM
Bioorg Chem; 2023 May; 134():106444. PubMed ID: 36893547
[TBL] [Abstract][Full Text] [Related]
15. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and modelling study of new 1,2,3-triazole/chalcone hybrids with antiproliferative action as epidermal growth factor receptor inhibitors.
Maghraby MT; Salem OIA; Youssif BGM; Sheha MM
Chem Biol Drug Des; 2023 Mar; 101(3):749-759. PubMed ID: 36366966
[TBL] [Abstract][Full Text] [Related]
17. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular docking of methoxy n-phenylpyrazoline derivatives as anticancer agents.
Wahyuningsih TD; Setiawati -; Tri Suma AA; Miggia Stansyah Y; Astuti E
Pak J Pharm Sci; 2022 Jul; 35(4):965-972. PubMed ID: 36008891
[TBL] [Abstract][Full Text] [Related]
19. Development and Assessment of 1,5-Diarylpyrazole/Oxime Hybrids Targeting EGFR and JNK-2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Shams R; Osawa K; Abdel-Aziz M; Konno H
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764297
[TBL] [Abstract][Full Text] [Related]
20. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
